<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2018.82019</article-id><article-id pub-id-type="publisher-id">ACM-24334</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20180200000_30470868.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  终末期肝病模型(MELD)评分联合血清甲胎蛋白和胆碱酯酶对乙型肝炎病毒相关慢加急性肝衰竭患者短期预后的评估价值
  Prediction of Model for End-Stage Liver Disease Combined with Serum Alpha-Fetoprotein and Cholinesterase Levels on the Short-Term Prognosis in Patients with Acute-on-Chronic Hepatitis B Liver Failure
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>涓</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>null</addr-line></aff><aff id="aff2"><label>1</label><addr-line>云南省第三人民医院消化内科，云南 昆明</addr-line></aff><author-notes><corresp id="cor1">* E-mail:</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>03</month><year>2018</year></pub-date><volume>08</volume><issue>02</issue><fpage>107</fpage><lpage>114</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨终末期肝病模型(MELD)评分联合血清甲胎蛋白(AFP)和胆碱酯酶(CHE)预测乙型肝炎病毒相关慢加急性肝衰竭(HBV-ACLF)患者短期预后的临床价值。方法：选取2008年1月~2015年12月我院住院的HBV-ACLF患者662例，随访3个月，生存416例和死亡246例，记录并比较两组患者血清谷丙转氨酶(ALT)、总胆红素(TBIL)、肌酐(Cr)、白蛋白(ALB)、AFP、CHE、国际标准化比值(INR)、血清钠(Na
   <sup>+</sup>)和MELD评分等临床资料。应用受试者工作特征曲线下面积(AUC)分析MELD评分联合血清AFP和CHE对HBV-ACLF患者短期预后的预测价值。结果：死亡组血清ALT (534.8 &#177; 45.1 U/L对438.5 &#177; 91.2 U/L)、TBIL (328.9 &#177; 71.9 μmol/L对244.5 &#177; 62.7 μmol/L)、Cr (96.9 &#177; 23.8 μmol/L对70.2 &#177; 22.3 μmol/L)、ALB (24.5 &#177; 6.8 g/L对28.7 &#177; 7.4 g/L)、AFP [21.5(7.6,50.4)μg/L对60.6(16.3,146.1)μg/L]、CHE (2.5 &#177; 1.2 kU/L对4.2 &#177; 1.4 kU/L)、INR (2.5 &#177; 1.1对2.1 &#177; 0.5)、MELD评分(26.3 &#177; 5.5对22.4 &#177; 5.2)均高于生存组，血清Na+水平(128.6 &#177; 13.1 mmol/L对132.8 &#177; 9.5 mmol/L)低于生存组，差异均有统计学意义(P均 &lt;0.001)；MELD评分、AFP、CHE预测HBV-ACLF患者近期死亡危险性的最佳截断点分别为24.8、20.6 μg/L、2.9 kU/L；MELD评分联合AFP和CHE判断HBV-ACLF患者短期预后的AUC为0.894，高于单独MELD评分AUC的0.834、AFPAUC的0.803或CHE AUC的0.621，差异均有统计学意义(P均 &lt;0.001)。结论：MELD评分联合血清AFP和CHE对HBV-ACLF患者短期预后的预测价值良好。
    Objective: To investigate the application of model for end-stage liver disease (MELD) scores, serum alpha-fetoprotein (AFP) and cholinesterase (CHE) levels in predicting the short-term prognosis of patients with hepatitis B virus related acute-on-chronic liver failure (HBV-ACLF). Methods: A total of 662 HBV-ACLF patients in Third People’s Hospital of Yunnan Province were recruited in this study, and 416 patients survived, while 246 died during three-month followed-up. Serum alanine aminotransferase (ALT), total bilirubin (TBIL), creatinine (Cr), albumin (ALB), AFP, CHE, in-ternational normalized ratio (INR) were measured, based on which MELD scores were calculated. The receiver operating characteristic curve (ROC) was used to evaluate the capability of MELD score combined with AFP and CHE for predicting the short-term prognosis of patients with HBV- ACLF. Results: Serum levels of ALT (534.8 &#177; 45.1 U/L vs 438.5 &#177; 91.2 U/L), TBIL (328.9 &#177; 71.9 μmol/L vs 244.5 &#177; 62.7 μmol/L), Cr (96.9 &#177; 23.8 μmol/L vs 70.2 &#177; 22.3 μmol/L), ALB (24.5 &#177; 6.8 g/L vs 28.7 &#177; 7.4 g/L) and AFP [21.5(7.6, 50.4)μg/L vs 60.6(16.3,146.1) μg/L], CHE (2.5 &#177; 1.2 kU/L vs 4.2 &#177; 1.4 kU/L), INR (2.5 &#177; 1.1 vs 2.1 &#177; 0.5), and the scores of MELD (26.3 &#177; 5.5 vs 22.4 &#177; 5.2) were significantly higher in the death group than in the survival group, while the serum level of Na
   <sup>+</sup> (128.6 &#177; 13.1 mmol/L vs 132.8 &#177; 9.5 mmol/L) was significantly lower in the death group than in the survival group (all P &lt; 0.001). The optimal cut-off value of MELD, and serum level of AFP and CHE were 24.8, 20.6 μg/L and 2.9 kU/L; The AUC of MELD score with AFP was 0.894, which was higher than 0.834 only by MELD score, 0.803 by AFP or 0.621 by CHE within 3-month for patients with HBV-ACLF. Conclusion: MELD score combined with serum AFP and CHE has a good predictive value on the short-term prognosis in patients with HBV-ACLF. 
  
 
</p></abstract><kwd-group><kwd>慢加急性肝衰竭，乙型肝炎，预后，胆碱酯酶，甲胎蛋白, Acute-on-Chronic Liver Failure</kwd><kwd> Chronic Hepatitis B</kwd><kwd> Prognosis</kwd><kwd> Cholinesterase</kwd><kwd> Alpha-Fetoprotein</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>终末期肝病模型(MELD)评分联合血清甲胎蛋白和胆碱酯酶对乙型肝炎病毒相关慢加急性肝衰竭患者短期预后的评估价值<sup> </sup></title><p>杨 涓</p><p>云南省第三人民医院消化内科，云南 昆明</p><p><img src="//html.hanspub.org/file/3-1570480x1_hanspub.png" /></p><p>收稿日期：2018年3月4日；录用日期：2018年4月2日；发布日期：2018年4月9日</p><disp-formula id="hanspub.24334-formula21"><graphic xlink:href="//html.hanspub.org/file/3-1570480x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨终末期肝病模型(MELD)评分联合血清甲胎蛋白(AFP)和胆碱酯酶(CHE)预测乙型肝炎病毒相关慢加急性肝衰竭(HBV-ACLF)患者短期预后的临床价值。方法：选取2008年1月~2015年12月我院住院的HBV-ACLF患者662例，随访3个月，生存416例和死亡246例，记录并比较两组患者血清谷丙转氨酶(ALT)、总胆红素(TBIL)、肌酐(Cr)、白蛋白(ALB)、AFP、CHE、国际标准化比值(INR)、血清钠(Na<sup>+</sup>)和MELD评分等临床资料。应用受试者工作特征曲线下面积(AUC)分析MELD评分联合血清AFP和CHE对HBV-ACLF患者短期预后的预测价值。结果：死亡组血清ALT (534.8 &#177; 45.1 U/L对438.5 &#177; 91.2 U/L)、TBIL (328.9 &#177; 71.9 μmol/L对244.5 &#177; 62.7 μmol/L)、Cr (96.9 &#177; 23.8 μmol/L对70.2 &#177; 22.3 μmol/L)、ALB (24.5 &#177; 6.8 g/L对28.7 &#177; 7.4 g/L)、AFP [21.5(7.6,50.4)μg/L对60.6(16.3,146.1)μg/L]、CHE (2.5 &#177; 1.2 kU/L对4.2 &#177; 1.4 kU/L)、INR (2.5 &#177; 1.1对2.1 &#177; 0.5)、MELD评分(26.3 &#177; 5.5对22.4 &#177; 5.2)均高于生存组，血清Na<sup>+</sup>水平(128.6 &#177; 13.1 mmol/L对132.8 &#177; 9.5 mmol/L)低于生存组，差异均有统计学意义(P均 &lt;0.001)；MELD评分、AFP、CHE预测HBV-ACLF患者近期死亡危险性的最佳截断点分别为24.8、20.6 μg/L、2.9 kU/L；MELD评分联合AFP和CHE判断HBV-ACLF患者短期预后的AUC为0.894，高于单独MELD评分AUC的0.834、AFPAUC的0.803或CHE AUC的0.621，差异均有统计学意义(P均 &lt;0.001)。结论：MELD评分联合血清AFP和CHE对HBV-ACLF患者短期预后的预测价值良好。</p><p>关键词 :慢加急性肝衰竭，乙型肝炎，预后，胆碱酯酶，甲胎蛋白</p><disp-formula id="hanspub.24334-formula22"><graphic xlink:href="//html.hanspub.org/file/3-1570480x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by author and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1570480x7_hanspub.png" /> <img src="//html.hanspub.org/file/3-1570480x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>本肝衰竭是临床常见的危重症之一，病情进展快，预后差，如未及时予以干预和治疗，患者病死率可高达60%~80%。目前我国大部分肝衰竭患者有慢性HBV感染基础，乙型肝炎病毒相关慢加急性肝衰竭(hepatitis B virus related acute-on-chronic liver failure, HBV-ACLF)是国内最常见的肝衰竭类型，也是我国慢性肝病最常见的死亡原因 [<xref ref-type="bibr" rid="hanspub.24334-ref1">1</xref>] 。近年来，随着内科综合治疗措施的优化，及人工肝技术的改良，肝衰竭患者的病死率有所下降 [<xref ref-type="bibr" rid="hanspub.24334-ref2">2</xref>] ，如何对肝衰竭患者的临床预后进行准确判断有利于后续正确治疗决策的选择 [<xref ref-type="bibr" rid="hanspub.24334-ref3">3</xref>] 。以往临床评价肝衰竭预后的单项指标包括血清钠(Na<sup>+</sup>)、血清总胆红素(TBIL)、凝血酶原时间(PT)等 [<xref ref-type="bibr" rid="hanspub.24334-ref4">4</xref>] ，但这些指标的预测准确性均较差。2001年Kamath提出了终末期肝病模型(MELD)，其后该模型评分被广泛应用于各类终末期肝病的预后评估 [<xref ref-type="bibr" rid="hanspub.24334-ref5">5</xref>] 。肝衰竭期间由于肝细胞再生因而血清甲胎蛋白(AFP)往往有不同程度的升高，而肝细胞再生的速度和数量对HBV-ACLF患者的预后影响较大 [<xref ref-type="bibr" rid="hanspub.24334-ref6">6</xref>] 。胆碱酯酶(CHE)在肝脏合成，也是一项反映肝脏受损程度和储备功能的敏感治疗 [<xref ref-type="bibr" rid="hanspub.24334-ref7">7</xref>] 。本研究旨在探讨MELD评分联合血清AFP和CHE对HBV-ACLF患者短期预后的预测价值。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 研究对象</title><p>选择2008年1月~2016年12月期间云南省第三人民医院住院的资料完备的HBV-ACLF患者662例作为研究对象，其中男392例，女270例；年龄18~72岁，平均年龄(45.5 &#177; 11.2)岁。HBV-ACLF的诊断符合2006年《肝衰竭诊疗指南》和2012年《肝衰竭诊治指南》中的标准 [<xref ref-type="bibr" rid="hanspub.24334-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.24334-ref9">9</xref>] 。排除标准：① 由HCV、HEV等其他类型肝炎病毒感染导致的肝衰竭；② 肝衰竭病因是乙醇、药物及其他中毒因素等；③ 伴有心肺功能不全及呼吸、循环功能障碍；④ 急性心、脑梗死处于非稳定期者；⑤ 伴有肾脏基础疾病及各种原因所致肾功能不全；⑥ 妊娠期妇女及儿童患者；⑦ 由于其他疾病需长期抗凝治疗者；⑧ 肝细胞癌或其他恶性肿瘤伴随肝脏转移者。所有患者均采用了个体化内科综合治疗，包括抗病毒、护肝、退黄、促肝细胞生长、补充白蛋白、调节免疫功能治疗等。根据患者病情进行血液净化和(或)血浆置换治疗。记录所有患者住院期间和出院3个月后的病情转归情况。本研究已获得云南省第三人民医院医学伦理委员会批准，并获得所有患者的书面知情同意。</p></sec><sec id="s4_2"><title>2.2. 研究方法</title><sec id="s4_2_1"><title>2.2.1. 检测指标及评分</title><p>使用LH750全自动血细胞分析仪(美国贝克曼库尔特公司)检测血常规；使用CI8200全自动生化分析仪(美国雅培公司)及配套试剂检测血生化指标；使用CA50自动凝血仪(日本东亚公司)检测凝血酶原时间(PT)并计算国际标准化比值(INR)；使用全自动免疫分析仪(美国BD公司)检测AFP。取患者入院时第一次检测指标，计算MELD分值 [<xref ref-type="bibr" rid="hanspub.24334-ref10">10</xref>] ，MELD分值= 3.8 &#215;In(TBIL) + 11.2 &#215; In(INR) + 9.6 &#215; In(Cr) + 6.4 &#215; 病因(病因：胆汁性或酒精性为0，其他为1)。按参考文献 [<xref ref-type="bibr" rid="hanspub.24334-ref11">11</xref>] 计算CTP评分。</p></sec><sec id="s4_2_2"><title>2.2.2. 统计学处理</title><p>应用SPSS 18.0软件进行统计学分析。计量资料以(x &#177; s)或[M(P25，P75)]表示。满足正态分布并且方差齐的两组资料比较采用独立样本t检验，不满足正态分布或方差不齐时，两组间比较采用Mann-Whitney U秩和检验(即U检验)；对方差齐的多组间资料的比较采用单因素方差分析，对方差不齐者采用Kruskal-Waillis H检验；计数资料以率表示，组间比较采用x<sup>2</sup>检验。采用Pearson相关分析。应用受试者工作特征曲线(ROC)评估不同评价方法对于HBV-ACLF患者短期预后的预测能力，并计算出预测患者死亡危险性的最佳截断点(cut-off value)和Youden指数，P &lt; 0.05被认为差异有统计学意义。</p></sec></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 生存与死亡患者一般资料比较</title><p>随访三个月后，662例HBV-ACLF患者生存者416例，死亡246例。生存组患者年龄、性别比例、白细胞(WBC)、血红蛋白(Hb)、血小板(PLT)等指标与死亡组相比，差异无统计学意义(P &gt; 0.05)；生存组血清谷丙转氨酶(ALT)、总胆红素(TBIL)、白蛋白(ALB)、碱性磷酸酶(ALP)、CHE、肌酐(Cr)、AFP、PT、INR、MELD分值、CTP分值等均明显低于死亡组，血清Na<sup>+</sup>水平明显高于死亡组，差异均有统计学意义(P &lt; 0.001，表1)。</p></sec><sec id="s5_2"><title>3.2. 相关性分析</title><p>662例HBV-ACLF患者入院后对血清AFP与CHE水平行相关性分析，两者无显著相关性[41.8(6.1, 155.4) μg/L vs (3.6 &#177; 1.4) kU/L，r = 0.081，P = 0.608]。</p></sec><sec id="s5_3"><title>3.3. 不同分期肝衰竭患者MELD评分及血清AFP和CHE水平比较</title><p>晚期肝衰竭MELD评分明显高于中期和早期患者，中期肝衰竭MELD评分明显高于早期患者，差异均有统计学意义(H = 36.295，P &lt; 0.001)；MELD评分与肝衰竭分期呈正相关(Spearman相关系数r = 0.485，P &lt; 0.001)；患者血清AFP和CHE水平随着ACLF分期加重而逐步降低(F = 19.575，H = 32.366，均P &lt; 0.001)；血清AFP和CHE水平与肝衰竭分期呈负相关(Spearman相关系数r = −0.419，r = −0.385，P &lt; 0.001，表2)。</p></sec><sec id="s5_4"><title>3.4. MELD评分联合血清AFP和CHE水平评估HBV-ACLF患者短期预后的预测价值</title><p>绘制MELD评分、AFP、CHE及多项联合的ROC曲线，结果MELD评分联合AFP和CHE预测</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison for two groups of general clinical data [n, (x &#177; s), M(P25, P75)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >生存组</th><th align="center" valign="middle" >死亡组</th><th align="center" valign="middle" >统计值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >男/女</td><td align="center" valign="middle" >250/166</td><td align="center" valign="middle" >142/104</td><td align="center" valign="middle" >χ<sup>2</sup> = 0.412</td><td align="center" valign="middle" >0.273</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >45.5 &#177; 10.3</td><td align="center" valign="middle" >46.3 &#177; 12.0</td><td align="center" valign="middle" >t = 0.584</td><td align="center" valign="middle" >0.089</td></tr><tr><td align="center" valign="middle" >WBC(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >7.4 &#177; 3.1</td><td align="center" valign="middle" >8.2 &#177; 3.4</td><td align="center" valign="middle" >t = −1.202</td><td align="center" valign="middle" >0.263</td></tr><tr><td align="center" valign="middle" >Hb(g/L)</td><td align="center" valign="middle" >124.5 &#177; 17.2</td><td align="center" valign="middle" >120.2 &#177; 8.6</td><td align="center" valign="middle" >t = −1.124</td><td align="center" valign="middle" >0.232</td></tr><tr><td align="center" valign="middle" >PLT(&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >90.5 &#177; 20.0</td><td align="center" valign="middle" >88.6 &#177; 18.8</td><td align="center" valign="middle" >t = 0.215</td><td align="center" valign="middle" >0.724</td></tr><tr><td align="center" valign="middle" >ALT(U/L)</td><td align="center" valign="middle" >438.5 &#177; 91.2</td><td align="center" valign="middle" >534.8 &#177; 45.1</td><td align="center" valign="middle" >t = 5.776</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >TBIL(μmol/L)</td><td align="center" valign="middle" >244.5 &#177; 62.7</td><td align="center" valign="middle" >328.9 &#177; 71.9</td><td align="center" valign="middle" >t = 4.639</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >ALB(g/L)</td><td align="center" valign="middle" >28.7 &#177; 7.4</td><td align="center" valign="middle" >24.5 &#177; 6.8</td><td align="center" valign="middle" >t = −3.989</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >ALP(U/L)</td><td align="center" valign="middle" >107.8 &#177; 27.2</td><td align="center" valign="middle" >148.6 &#177; 48.1</td><td align="center" valign="middle" >t = 9.088</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >CHE(kU/L)</td><td align="center" valign="middle" >4.2 &#177; 1.2</td><td align="center" valign="middle" >2.5 &#177; 1.2</td><td align="center" valign="middle" >t = −4.422</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >Cr(μmol/L)</td><td align="center" valign="middle" >70.2 &#177; 22.3</td><td align="center" valign="middle" >96.9 &#177; 23.8</td><td align="center" valign="middle" >t = 4.715</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >Na<sup>+</sup>(mmol/L)</td><td align="center" valign="middle" >132.8 &#177; 9.5</td><td align="center" valign="middle" >128.6 &#177; 13.1</td><td align="center" valign="middle" >t = 5.165</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >AFP(μg/L)</td><td align="center" valign="middle" >60.6(16.3, 146.1)</td><td align="center" valign="middle" >21.5(7.6, 50.4)</td><td align="center" valign="middle" >U = 7.374</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >PT(s)</td><td align="center" valign="middle" >22.5 &#177; 4.2</td><td align="center" valign="middle" >28.2 &#177; 6.5</td><td align="center" valign="middle" >t = −5.528</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >INR</td><td align="center" valign="middle" >2.1 &#177; 0.5</td><td align="center" valign="middle" >2.5 &#177; 1.1</td><td align="center" valign="middle" >U = −4.384</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >MELD评分</td><td align="center" valign="middle" >22.4 &#177; 5.2</td><td align="center" valign="middle" >26.3 &#177; 5.5</td><td align="center" valign="middle" >t = −6.754</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >CTP评分</td><td align="center" valign="middle" >10.2 &#177; 1.1</td><td align="center" valign="middle" >12.2 &#177; 1.3</td><td align="center" valign="middle" >t = −5.390</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><p>表1. 两组一般临床资料[n, (x &#177; s), M(P25, P75)]比较</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The MELD scores and serum AFP and CHE were compared in 662 patients with different stages of liver failure (x &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >肝衰竭分期</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >MELD评分</th><th align="center" valign="middle" >AFP (μg/L)</th><th align="center" valign="middle" >CHE (kU/L)</th></tr></thead><tr><td align="center" valign="middle" >早期</td><td align="center" valign="middle" >174</td><td align="center" valign="middle" >20.3 &#177; 4.2</td><td align="center" valign="middle" >40.2(14.5, 96.6)</td><td align="center" valign="middle" >4.2 &#177; 1.3</td></tr><tr><td align="center" valign="middle" >中期</td><td align="center" valign="middle" >348</td><td align="center" valign="middle" >23.1 &#177; 4.5<sup>①</sup></td><td align="center" valign="middle" >24.3(10.8, 67.4)<sup>①</sup></td><td align="center" valign="middle" >3.6 &#177; 1.2<sup>①</sup></td></tr><tr><td align="center" valign="middle" >晚期</td><td align="center" valign="middle" >140</td><td align="center" valign="middle" >28.5 &#177; 6.6<sup>①②</sup></td><td align="center" valign="middle" >9.8(8.2, 15.6)<sup>①②</sup></td><td align="center" valign="middle" >2.5 &#177; 1.4<sup>①②</sup></td></tr></tbody></table></table-wrap><p>表2. 662例不同分期肝衰竭患者MELD评分及血清AFP和CHE (x &#177; s)比较</p><p>与早期比，<sup>①</sup>P &lt; 0.001；与中期比，<sup>x</sup>P &lt; 0.001</p><p>HBV-ACLF患者三个月死亡的AUC为0.894(P = 0.000)，大于MELD评分(AUC = 0.834，P = 0.000)或AFP(AUC = 0.803，P = 0.000)或CHE(AUC = 0.621，P = 0.03)；以敏感度和特异度之和最大者为截断点，MELD评分为24.8时，其敏感度为85.6%，特异度为81.7%；AFP ≥ 20.6μg/L时，预测HBV-ACLF患者三个月死亡的敏感度为80.8%，特异度为77.6%；以CHE ≥ 2.9 kU/L时，预测HBV-ACLF患者三个月死亡的敏感度为75.9%，特异度为65.3%；采用MELD ≥ 24.8联合AFP ≥ 20.6 μg/L和CHE ≥ 2.9 kU/L时，其敏感度为91.0%，特异度为88.4%(图1、表3)。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>2001年Kamath等人创立了终末期肝病模型(MELD)评分，该模型为多项客观指标的组合，主要用于预测经颈静脉肝内门体分流术后肝硬化门静脉高压患者的预后。由于MELD评分所选变量均为客观指标，且在临床工作中较易获取，具有较好的预测准确性，逐步被推广应用于预测各类型严重肝病患者的预后。本研究结果发现死亡组与生存组之间MELD评分差异具有统计学意义，并且MELD分值越大，病死率越高，与文献报道结果一致 [<xref ref-type="bibr" rid="hanspub.24334-ref12">12</xref>] 。随着对MELD评分系统研究的深入，各种在MELD评分基础上建立的改良模型不断出现，并较MELD评分有了更好的预测价值。Rufetal等人 [<xref ref-type="bibr" rid="hanspub.24334-ref13">13</xref>] 将终末期肝病的独立预测因素血清钠和MELD评分结合，建立了MELD-Na模型；iMELD模型在结合了患者血清钠基础之上，兼顾患者整体的机体情况，再将年龄因素纳入。在MELD-Na基础上，Huo等 [<xref ref-type="bibr" rid="hanspub.24334-ref14">14</xref>] 建立了MESO预测模型。但必须指出的是，慢加急性肝衰竭患者较普通的肝硬化和(或)慢性肝衰竭患者病病程进展更为复杂，单一量化指标或已有的预测评分模型对于疾病预后的预测仍有不足。一项对327例HBV-ACLF患者的回顾性研究显示，包括MELD、MELD-Na、iMELD等在内的多项评分体系对该类患者的预后准确性仍不尽如人意 [<xref ref-type="bibr" rid="hanspub.24334-ref15">15</xref>] 。国内也有研究 [<xref ref-type="bibr" rid="hanspub.24334-ref16">16</xref>] 表明MELD、MELD-Na、iMELD对患者12周预后预测的ROC曲线下面积仅分别为0.731、0.735、0.773，敏感度均在0.7以下。为了解决ACLF患者临床预后的预测问题，众多学者先后制定了评价ALCF患者预后的危险因素和数学模型，其中一些模型由于本身选择指标较大，计算应用过程较为复杂而不易被临床推广应用；另一些模型由于存在样本量少、资料不完全、病种构成复杂等问题，预测准确性欠佳而难以得到公认。目前国内ACLF的疾病基础很大一部分是由于HBV感染所致，因此，找寻能适用于我国HBV-ACLF患者短期预后的预测模型十分必要。</p><p>近年来针对ACLF的发病机制研究有了新的发现，即“三重打击学说”，即在各种病因所致免疫调节紊乱、微循环障碍、内毒素血症等作用下可导致大量肝细胞坏死、凋亡 [<xref ref-type="bibr" rid="hanspub.24334-ref17">17</xref>] ，从而诱发肝脏功能衰竭，而肝细胞大量坏死及缺乏有效的再生可进一步加剧肝衰竭病情恶化。因此，准确了解肝细胞坏死情况及肝细胞再生速度数量对判断ACLF患者的预后有较好的参考意义。血清AFP由幼稚肝细胞分泌，主要在胎儿期合成；在成人中血清AFP一般作为肿瘤标志物用于肝细胞癌的诊断，血清AFP异常增高往往提示肝脏可能有恶性占位性病变。有研究表明，肝脏手术后血清AFP可有不同程度的升高，提示AFP升高可</p><p>图1. MELD评分联合AFP和CHE对HBV-ACLF患者近期预后判断的ROC曲线</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> MELD score combined with serum AFP and CHE’s predictive value for the death of HBV-ACLF patients in 3 month</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >截断点</th><th align="center" valign="middle" >AUC</th><th align="center" valign="middle" >95%置信区间</th><th align="center" valign="middle" >灵敏度</th><th align="center" valign="middle" >特异度</th><th align="center" valign="middle" >Youden指数</th></tr></thead><tr><td align="center" valign="middle" >MELD</td><td align="center" valign="middle" >≥24.8</td><td align="center" valign="middle" >0.834</td><td align="center" valign="middle" >0.732~0.937</td><td align="center" valign="middle" >85.6</td><td align="center" valign="middle" >81.7</td><td align="center" valign="middle" >0.618</td></tr><tr><td align="center" valign="middle" >AFP</td><td align="center" valign="middle" >≥20.6 μg/L</td><td align="center" valign="middle" >0.803</td><td align="center" valign="middle" >0.678~0.929</td><td align="center" valign="middle" >80.8</td><td align="center" valign="middle" >77.6</td><td align="center" valign="middle" >0.586</td></tr><tr><td align="center" valign="middle" >CHE</td><td align="center" valign="middle" >≥2.9 kU/L</td><td align="center" valign="middle" >0.621</td><td align="center" valign="middle" >0.470~0.773</td><td align="center" valign="middle" >75.9</td><td align="center" valign="middle" >65.3</td><td align="center" valign="middle" >0.368</td></tr><tr><td align="center" valign="middle" >MELD/AFP/CHE</td><td align="center" valign="middle" >≥24.8/≥20.6 μg/L/≥2.9 kU/L</td><td align="center" valign="middle" >0.894</td><td align="center" valign="middle" >0.803~0.985</td><td align="center" valign="middle" >91.0</td><td align="center" valign="middle" >88.4</td><td align="center" valign="middle" >0.669</td></tr></tbody></table></table-wrap><p>表3. MELD评分联合血清AFP和CHE对HBV-ACLF患者3月死亡的预测价值</p><p>作为肝细胞大量再生的标志。另一项研究 [<xref ref-type="bibr" rid="hanspub.24334-ref18">18</xref>] 也证实，ACLF患者AFP升高提示预后较好。本研究中HBV-ACLF患者血清AFP水平随着ACLF分期加重而逐步降低，与患者病情严重程度呈负相关，因此，在ACLF患者中，血清AFP水平可作为判断病情严重程度及肝细胞再生的重要参考指标。CHE主要在肝脏合成，随着肝脏损伤的加剧，其合成CHE的能力随之下降。多项临床研究也证实血清CHE水平能反映肝脏的损伤程度及肝脏剩余储备功能 [<xref ref-type="bibr" rid="hanspub.24334-ref19">19</xref>] 。本研究结果表明，血清AFP、CHE与HBV-ACLF患者病死率之间存在线性关系。随着AFP及CHE的降低，病死率也逐渐增高，与另一研究 [<xref ref-type="bibr" rid="hanspub.24334-ref20">20</xref>] 报道一致。本研究观察到，在肝衰竭早、中、晚期患者，MELD评分及AFP、CHE均有不同的改变，一定程度上都准确反应了肝衰竭病情的严重程度。本研究进一步应用ROC曲线分析发现，MELD评分和血清AFP的AUC均 &gt; 0.8，均有好的预测准确性，均能够较好地预测HBV-ACLF患者的短期预后。其中，MELD评分联合AFP、CHE的AUC为0.894，大于单独MELD评分AUC的0.834、单独AFP AUC的0.803和单独CHEAUC的0.621。此外，采用MELD ≥ 24.8联合AFP ≥ 20.6μg/L联合CHE ≥ 2.9 kU/L时，其敏感度为91.0%，特异度为88.4%，提示应用MELD评分联合血清AFP和CHE可提高对HBV-ACLF患者短期预后的准确性，具有较好的临床应用价值。</p><p>ACLF早期预后的判断对于ACLF治疗方案的制定及后续抢救成功率的提高具有重要意义，因此其相关研究始终是急慢性肝病研究领域的热点问题 [<xref ref-type="bibr" rid="hanspub.24334-ref21">21</xref>] 。但由于ACLF的发病机制复杂、临床表现和并发症表现的多样化以及不同患者个体差异较大等一系列的原因，现有的反映ACLF预后的评价系统仍不完善。通过不断引入更能确切反映ACLF病情严重程度和与预后判断相关的标志物，扩大验证和完善现有的评估系统很有意义。本研究在原有的MELD评分系统基础上，引入了反映肝脏再生及剩余储备功能的生物学指标AFP和CHE，强调了损伤-再生因素对HBV-SACLF预后的影响，更优于单纯的MELD评分，但本研究样本量有限，针对MELD评分系统基础上加入其它指标的优化值得进一步研究。</p></sec><sec id="s7"><title>基金项目</title><p>云南省自然科学基金青年项目(编号：2012FD095)；云南省教育厅科研基金重点项目(编号：2014Z125/2015Z146)；云南省临床重点专科建设项目(编号：云卫医发(2015)18号)。</p></sec><sec id="s8"><title>文章引用</title><p>杨 涓. 终末期肝病模型(MELD)评分联合血清甲胎蛋白和胆碱酯酶对乙型肝炎病毒相关慢加急性肝衰竭患者短期预后的评估价值 Prediction of Model for End-Stage Liver Disease Combined with Serum Alpha-Fetoprotein and Cholinesterase Levels on the Short-Term Prognosis in Patients with Acute-on-Chronic Hepatitis B Liver Failure[J]. 临床医学进展, 2018, 08(02): 107-114. https://doi.org/10.12677/ACM.2018.82019</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.24334-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y., Hu, X.Y., Zhong, S., et al. (2014) Entecavir vs Lamivudine Therapy for Native Patients with Spontaneous Reactivation of Hepatitis B Presenting as Acute-on-Chronic Liver Failure. World Journal of Gastroenterology, 20, 4745-4752. https://doi.org/10.3748/wjg.v20.i16.4745</mixed-citation></ref><ref id="hanspub.24334-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Katoonizadeh, A., Laleman, W., Verslype, C., et al. (2010) Early Features of Acute-on-Chronic Alcoholic Liver Failure: A Prospective Cohort Study. Gut, 59, 1561-1569. https://doi.org/10.1136/gut.2009.189639</mixed-citation></ref><ref id="hanspub.24334-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">丁淑芬, 徐立新, 蔡晓娟. MELD对慢加急性肝衰竭预后的判断价值[J]. 肝脏, 2011, 16(6): 506-507.</mixed-citation></ref><ref id="hanspub.24334-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">吴婧, 倪鎏达, 江浦柱. MELD-EHBF模型建立及其对ACLF预后价值[J]. 肝脏, 2015, 20(6): 447-461.</mixed-citation></ref><ref id="hanspub.24334-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Kamath, P.S., Wisener, R.H., Malinchoc, M., et al. (2001) A Model to Predict Survival in Patients with End-Stage Liver Disease. Hepatology, 33, 464-470. https://doi.org/10.1053/jhep.2001.22172</mixed-citation></ref><ref id="hanspub.24334-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ulasli, S.S., Ozyurek, B.A., Yilmaz, E.B., et al. (2012) Al-pha-Fetoprotein as an Inflammatory Marker in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Polskie Archiwum Medycyny Wewnetrznej, 122, 84-290.</mixed-citation></ref><ref id="hanspub.24334-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">阮承兰, 张俊飞, 宋海燕, 等. 肝衰竭预后影响因素的Logistic回归分析[J]. 中华疾病控制杂志, 2014, 18(6): 537-540.</mixed-citation></ref><ref id="hanspub.24334-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组. 肝衰竭诊疗指南[J]. 实用肝脏病杂志, 2006(9): 321-324.</mixed-citation></ref><ref id="hanspub.24334-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会感染病学分会肝衰竭与人工肝学组和肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南[J]. 实用肝脏病杂志, 2013, 16(3): 210-216.</mixed-citation></ref><ref id="hanspub.24334-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Silberhumer, G.R., Hetz, H., Rasoul-Rockenschaub, S., et al. (2006) Is MELD Score Sufficient to Predict Not Only Death on Waiting List, but Also Post-Transplant Survival? Transplant International, 19, 275-281.  
https://doi.org/10.1111/j.1432-2277.2006.00250.x</mixed-citation></ref><ref id="hanspub.24334-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Shakil, A.O., Kramer, D., Mazariegos, G.V., et al. (2000) Acute Liver Failure: Clinical Feature, Outcome Analysis, and Applicability of Prognostic Criteria. Liver Transplantation, 6, 163-169. https://doi.org/10.1002/lt.500060218</mixed-citation></ref><ref id="hanspub.24334-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, M.H., Shi, K.Q., Lin, X.F., et al. (2013) A Model to Predict 3-Month Mortality Risk of Acute-on-Chronic Hepatitis B Liver Failure Using Artificial Neural Network. Journal of Viral Hepatitis, 20, 248-255.  
https://doi.org/10.1111/j.1365-2893.2012.01647.x</mixed-citation></ref><ref id="hanspub.24334-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ruf, A.E., Kremers, W.K., Chavez, L.L., et al. (2005) Addition of Serum Sodium into the MELD Score Predicts Waiting List Mortality Better than MELD Alone. Liver Transplantation, 11, 336-343. https://doi.org/10.1002/lt.20329</mixed-citation></ref><ref id="hanspub.24334-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Huo, T.I., Lin, H.C., Huo, S.C., et al. (2008) Comparison of Four Model for End-Stage Liver Disease-Based Prognostic Systems for Cirrhosis. Liver Transplantation, 14, 837-844. https://doi.org/10.1002/lt.21439</mixed-citation></ref><ref id="hanspub.24334-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Zaman, M.B., Hoti, E., Qasim, A., et al. (2006) MELD Score as a Prognostic Model for Listing Acute Liver Failure Patients for Liver Transplantation. Transplantation Proceedings, 38, 2097-2098.  
https://doi.org/10.1016/j.transproceed.2006.06.004</mixed-citation></ref><ref id="hanspub.24334-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Garg, H., Kumar, A., Garg, V., et al. (2012) Clinical Profile and Predictors of Mortality in Patients of Acute-on- Chronic Liver Failure. Digestive and Liver Disease, 44, 166-171. https://doi.org/10.1016/j.dld.2011.08.029</mixed-citation></ref><ref id="hanspub.24334-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">叶一农, 高志良. 乙型肝炎肝衰竭发生机制中的三重打击[J]. 传染病信息, 2009, 22(5): 276-279.</mixed-citation></ref><ref id="hanspub.24334-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">徐少卿, 郭建彪, 李红艳, 等. 血清甲胎蛋白与慢加急性肝衰竭预后的关系[J]. 临床消化病杂志, 2014, 26(1): 46-47.</mixed-citation></ref><ref id="hanspub.24334-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">王艳丽, 黎环. 乙型肝炎肝衰竭患者预后影响因素研究[J]. 胃肠病学和肝病学杂志, 2014, 23(10): 1191-1194.</mixed-citation></ref><ref id="hanspub.24334-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">苗静, 吴素琼, 郭丽颖, 等. 甲胎蛋白和胆碱酯酶在乙型肝炎病毒相关慢加急性肝衰竭患者中应用价值的研究[J]. 中华危重病急救医学, 2016, 28(3): 257-260.</mixed-citation></ref><ref id="hanspub.24334-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Tritto, G., Davies, N.A. and Jalan, R. (2012) Liver Replacement Therapy. Seminars in Respiratory and Critical Care Medicine, 33, 70-79. https://doi.org/10.1055/s-0032-1301736</mixed-citation></ref></ref-list></back></article>